Germany's "National Decade Against Post-Infectious Diseases"

Possibly. Isatuximab wasn't mentioned explicitly, only her group.

Edit: speak of the devil



I feel like I'm missing something. Is Uplinza funding separate from the National Decade against Post-Infectious Diseases?

From the linked page:
In 2026, for example, a newly designed Phase II study on the efficacy and safety of the monoclonal antibody Uplizna will start.

From previous post:
For this reason, the initial research funding guidelines will not aim to promote individual therapies or specific drug candidates.
 
From reading in the other thread it seems like she wants to do cd20 as well as cd19 and cd38 maybe? I mean at least we'll get some really concrete answers on that and put the rituximab debate to bed at last if they do that.
If uses proper methodology.
IIRC her team has had a history of spinning negative results as positive so not holding my breath.
 
Auf Deutsch:

Google translation:
  1. Research
  2. Health

Post-infectious diseases

Medical research

Effective treatment options for post-infectious diseases such as Long COVID or ME/CFS are currently lacking. The National Decade Against Post-Infectious Diseases is elucidating the causes and mechanisms and gradually laying the foundation for the development of new therapeutic options.
Covid

Opportunities

  • Post-infectious diseases represent an immense burden for those affected and their families.
  • The National Decade Against Post-Infectious Diseases aims to improve our understanding of the causes and mechanisms of post-infectious diseases. Research is being expanded and gradually transferred from the laboratory to the patient's bedside.
  • The aim is to improve the care provided to those affected.

Contents​


National Decade Against Post-Infectious Diseases (2026–2035)

The National Decade Against Post-Infectious Diseases is a ten-year initiative of the Austrian Federal Ministry for Digital and Economic Affairs (BMFTR), implemented in cooperation with health research partners. Its aim is to investigate the causes, underlying mechanisms, and new treatment options for those affected by post-infectious diseases such as ME/CFS and many post-viral illnesses.








Research funding from the BMFTR

With €500 million, the decade is establishing a long-term strategy for researching post-infectious diseases. Worldwide, there are currently no evidence-based therapies for the effective treatment of illnesses such as Long COVID, Post-COVID Syndrome, or ME/CFS. These diseases are complex and manifest in highly variable ways, which is why current therapies are limited to treating symptoms. A key focus is on researching the disease mechanisms – only by understanding the causes and biological processes can targeted new diagnostic and therapeutic methods be developed.

Planned research measures

The following are planned:

  • Additional funding for various research projects in the areas of pathophysiology and immunology, diagnostics and biomarkers, neurology and mental health, as well as long-term consequences of ME/CFS.
  • Strengthening clinical trials
  • Structural measures such as the promotion of junior research groups to increase the number of scientific experts in the long term.
  • Establishing a new patient database as a basis for research projects and for testing new therapeutic approaches
  • Genome sequencing: The NAKO health study – Germany's largest long-term study on widespread diseases – includes over 200,000 participants. Together with the cohorts of the NAPKON (National Pandemic Cohort Network) of the University Medicine Network, extensive health data is already available. The additional sequencing of the genomes of infected and unaffected participants reveals genetic differences. These findings form the basis for a better understanding of the disease mechanisms of post-infectious diseases.
  • Networking and training measures for the scientific community as well as evidence-based public relations work for the scientific community.

Frequently asked questions about post-infectious illnesses such as ME/CFS

Here we answer the most important questions about post-infectious diseases such as ME/CFS or Long-/Post-COVID and the research funding of the Federal Ministry for Research, Technology and Space (BMFTR).

The Austrian Federal Ministry for Digital and Economic Affairs (BMFTR) launched a funding call in May 2021 to research the late symptoms of COVID-19. Since 2022, the BMFTR has provided more than €64 million for research in the field of post-infectious diseases. The aim of this funding is to better understand the causes and mechanisms of post-infectious diseases and, based on this understanding, to develop new treatment options.

Launch of the National Decade Against Post-Infectious Diseases

To give research a decisive boost, the Federal Ministry for Digital and Economic Affairs (BMFTR), together with its health research partners, will launch a National Decade against Post-infectious Diseases in 2026. The decade will run for ten years, starting in 2026, and will have a total budget of 500 million euros.

In November 2025, Federal Research Minister Dorothee Bär and Federal Health Minister Nina Warken also launched the "Alliance for Post-Infectious Diseases: Long-COVID-19 and ME/CFS." With this initiative, the Federal Ministry of Health (BMG) and the Federal Ministry of Finance (BMFTR) are sending a clear signal of their commitment to strengthened interdepartmental collaboration. The alliance aims to more closely integrate basic and clinical research with health services research.

Open all
1. What are post-infectious diseases and what do we know about them?
2. What is ME/CFS? Is it the same as Long COVID?
3. How many people are affected?
4. How much does the BMFTR invest in research on Long-COVID and ME/CFS?
5. Has the BMFTR cut research funding?
6. What is the National Decade Against Post-Infectious Diseases?
7. Who decides on the content and structure of the National Decade against Post-infectious Diseases?
8. Can companies also apply for funding?
9. What is the "Alliance for Post-Infectious Diseases: Long-COVID and ME/CFS"?
10. Which projects are funded by the BMFTR and why?
11. Who decides on the selection of the projects that will be funded?
12. What long-term goals does the ministry pursue with this funding?
13. When does the BMFTR expect results?
14. How are research findings translated into medical practice?
15. When can drug candidates like MDC002 be tested on patients?
16. What role do patients and their organizations play in research?
17. How do the Federal Ministry of Health (BMG) and the Federal Ministry for Research, Technology and Space (BMFTR) cooperate on this issue?
18. Why are there hardly any clinical trials and therapies for affected individuals in Germany despite millions in funding?
19. Why is there so little drug research for post-infectious diseases?
20. Why does research into post-infectious diseases take so long?
21. What is the “post-vac syndrome” and are those affected taken into account?
22. How does the BMFTR inform the public about progress in research?
23. Where can I get more information?

 
Genome sequencing: The NAKO health study – Germany's largest long-term study on widespread diseases – includes over 200,000 participants. Together with the cohorts of the NAPKON (National Pandemic Cohort Network) of the University Medicine Network, extensive health data is already available. The additional sequencing of the genomes of infected and unaffected participants reveals genetic differences. These findings form the basis for a better understanding of the disease mechanisms of post-infectious diseases.
Anyone know more about this?
 
They're working on some sort of genetics project. The way I understand it is that they have 200k samples from the general population and they're currently analysing 35k of those - who may or may not have LC or ME/CFS.




But I agree, a collaboration with the University of Edinburgh would be good.
Here’s a new article about NAKO:

AI Summary:

National Decade Against Post-Infectious Diseases​

When the Infection Is Over – and the Illness Only Begins​


Post-infectious diseases such as Long Covid and ME/CFS are posing new medical and societal challenges. Using long-term data from the NAKO Health Study, Germany aims to systematically investigate why some infections leave lasting effects and how affected individuals can be better supported.

Post-infectious diseases are increasing. After infections such as Covid-19, chronic conditions like Long Covid or ME/CFS can develop months or even years later. In Germany, hundreds of thousands of people are affected. Expert estimates suggest that by the end of 2024, around 870,000 people were living with Long Covid and 650,000 with CFS.

The Federal Ministry of Research, Technology and Space is investing approximately 500 million euros over ten years as part of the “National Decade Against Post-Infectious Diseases.” The goal is to systematically research causes, disease mechanisms, diagnostics, and therapies, and to improve patient care. Around 50 million euros per year will fund interdisciplinary projects, data infrastructures, and clinical studies.

Post-infectious diseases sometimes emerge after the infection itself has already been overcome. Following a viral or other microbial infection, a new illness may develop after days or even years. This condition is thought to be triggered by processes that occurred during the infection.

One prominent example since the coronavirus pandemic is Long Covid, characterized by fatigue, reduced physical capacity, cognitive impairment (“brain fog”), and shortness of breath weeks to months after a SARS-CoV-2 infection. The frequency of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) has also increased. ME/CFS is a severe, chronic multisystem disease that often follows an infection and is marked by pronounced exhaustion that significantly worsens after exertion.

The Role of the NAKO Health Study​

The NAKO Health Study, Germany’s largest population-based long-term study, plays a central role in the initiative. Since 2014, around 200,000 men and women aged 20 to 69 have undergone medical examinations and regular surveys about their health, lifestyle, and environmental factors.

A major strength of NAKO is its ability to provide a rare before-and-after comparison, with data and biological samples collected before, during, and after the pandemic. Within the EpiPAIS (Epidemiology of Post-Acute Infection Syndromes) project, about 4,500 NAKO participants are being examined in greater detail to analyze such comparisons.

Researchers are investigating a broad range of possible mechanisms, as the exact causes of post-infectious diseases are not yet fully understood. Hypotheses include persistent immune dysregulation with chronic inflammation, autoimmune reactions, lingering viral components in the body, vascular dysfunction, microthrombi, autonomic nervous system changes, and metabolic or mitochondrial dysfunction. It is likely that multiple factors interact differently depending on the infection and individual predisposition.

The immune system appears to play a central role in most cases. Researchers are examining changes in leukocyte counts and epigenetic patterns of immune cells. They are also searching for protective biological or lifestyle-related factors that may prevent severe disease courses.

Determining Prevalence and Immune Profiles​

Another key objective is to determine how many people in Germany are affected by specific post-infectious diseases. Long Covid, for example, is not yet uniformly recorded, and its true prevalence remains unclear. Because NAKO closely follows its 200,000 participants, it may provide important insights into disease distribution.

An additional NAKO research project analyzes antibodies against various pathogens in several thousand participants. Researchers are studying how common these antibodies are, how strong they are, and how they change over time. Such serological analyses can help clarify how the immune system responded to past infections and which immune profiles may be linked to higher or lower risks of post-infectious diseases.

These data may reveal connections between previous infections, immune responses, and long-term health consequences. They could also help identify protective factors and inform the development of prevention and therapy strategies.

Overall, many fundamental questions remain: which viral infections are associated with which post-infectious diseases, which factors influence risk, and what contributes to recovery. The NAKO data and projects aim to help answer these questions and support the goals of the National Decade Against Post-Infectious Diseases.
 
Does anyone know if they will require the Autoantibodies again for the future Isatuximab trial, or if they were required for the Daratumumab trials?
I’m not sure I understand what you mean?

Autoantibodies are the antibodies the body creates itself that targets the body. Are you talking about doing tests for certain autoantibodies as a part of the inclusion criteria for the trials?

Fluge and Mella did not do that.
 
I’m not sure I understand what you mean?

Autoantibodies are the antibodies the body creates itself that targets the body. Are you talking about doing tests for certain autoantibodies as a part of the inclusion criteria for the trials?

Fluge and Mella did not do that.
Yes, a lot of research and treatments especially in Germany is around GCPR autoantibodies (beta1, beta2, m3, m4) so I am wondering if isatuximab will again exclude the patients without those aabs (measurement methods are doubtful, levels fluctuate and in many cases don’t correlate with severity)
 
Back
Top Bottom